4-butyrolactone has been researched along with Uterine Cervical Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chopade, BA; Ghosh, S; Pawar, VU; Shinde, VS | 1 |
| Hirata, E; Jin, HH; Komatsu, M; Mukai, K; Nagai, N; Yunokawa, M | 1 |
2 other study(ies) available for 4-butyrolactone and Uterine Cervical Neoplasms
| Article | Year |
|---|---|
Design and synthesis of harzialactone analogues: promising anticancer agents.
Topics: 4-Butyrolactone; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Drug Design; Drug Screening Assays, Antitumor; Female; Glucose; Humans; Lactones; Oxidation-Reduction; Stereoisomerism; Structure-Activity Relationship; Uterine Cervical Neoplasms | 2010 |
UFT and its metabolite gamma-butyrolactone (GBL) inhibit angiogenesis induced by vascular endothelial growth factor in advanced cervical carcinoma.
Topics: 4-Butyrolactone; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Immunohistochemistry; Middle Aged; Tegafur; Uracil; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A | 2008 |